• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

    2/14/24 4:17:18 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care
    Get the next $NYXH alert in real time by email
    SC 13G/A 1 tm245885d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1 )*

     

    Nyxoah SA

    (Name of Issuer)

     

    Ordinary Shares

    (Title of Class of Securities)

     

    B6S7WD106

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨     Rule 13d-1(b)

    ¨ Rule 13d-1(c)

    x    Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. B6S7WD106   13G   Page 2 of 5

     

    1.

    Names of Reporting Persons

     

    Robert Taub

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

     

    Belgium

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

    5.

    Sole Voting Power

     

    2,127,030

    6.

    Shared Voting Power

     

    1,263,484 (1)

    7.

    Sole Dispositive Power

     

    2,127,030

    8.

    Shared Dispositive Power

     

    1,263,484 (1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,390,514

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    ¨

    11.

    Percent of Class Represented by Amount in Row (9)

     

    11.8% (2)

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)Consists of (i) 696,000 Ordinary Shares held by Robelga SRL, a company which is 100% owned by BMI Estate, a partnership of which the Reporting Person maintains 100% control and (ii) 567,484 Ordinary Shares held by BMI Estate.
    (2)Based on 28,673,985 ordinary shares (“Ordinary Shares”) of Nyxoah S.A. (the “Issuer”) stated to be outstanding in the Issuer's Form 6-K furnished to the Securities and Exchange Commission (“SEC”) on December 11, 2023.

     

     

     

     

    CUSIP No. B6S7WD106   13G   Page 3 of 5

     

    Item 1.

      (a) Name of issuer
        Nyxoah SA (the “Issuer”).

      (b) Address of issuer’s principal executive offices
        Rue Edouard Belin 12,
        1435 Mont-Saint-Guibert, Belgium

     

    Item 2.

      (a) Name of person filing
        This Schedule 13G/A is being filed by Robert Taub (the “Reporting Person”).

      (b) Address or principal business office or, if none, residence
        The principal business office of the Reporting Person is c/o Nyxoah SA, Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium.

      (c) Citizenship
        The Reporting Person is a citizen of Belgium.

      (d) Title of class of securities
        This Statement refers to the Ordinary Shares of the Issuer.

      (e) CUSIP No.
        The CUSIP number of the ordinary shares is B6S7WD106.

     

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78c).
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
      (d) ¨ Investment company registered under section 8 of the Investment Company Act (15 U.S.C. 80a-8).
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E).
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(ii)(F).
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
      (k) ¨ Group in accordance with § 240.13d-1(b)(ii)(J).
           

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

     

     

    CUSIP No. B6S7WD106   13G   Page 4 of 5

     

    Item 4. Ownership
      The responses to Items 5-11 of the cover page of this Schedule 13G are incorporated herein by reference.

     

    (a)Amount beneficially owned: 3,390,514 Ordinary Shares

    (b)Percent of class: 11.8%*

    (c)Number of shares as to which the person has:

    (i)Sole power to vote or to direct the vote: 2,127,030

    (ii)Shared power to vote or to direct the vote: 1,263,484 **

    (iii)Sole power to dispose of or to direct the disposition of: 2,127,030

    (iv)Shared power to dispose of or to direct the disposition of: 1,263,484 **

     

    *Based on 28,673,985 Ordinary Shares of the Issuer stated to be outstanding in the Issuer's Form 6-K furnished to the SEC on December 11, 2023.
    **Consists of (i) 696,000 Ordinary Shares held by Robelga SRL, a company which is 100% owned by BMI Estate, a partnership of which the Reporting Person maintains 100% control and (ii) 567,484 Ordinary Shares held by BMI Estate.

     

    Item 5. Ownership of 5 Percent or Less of a Class.
      Not applicable.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.
      Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certifications.
      Not applicable.

     

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

      By: /s/ Robert Taub
      Name: Robert Taub

     

     

     

    Get the next $NYXH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NYXH

    DatePrice TargetRatingAnalyst
    7/31/2023Buy
    H.C. Wainwright
    7/19/2023Neutral
    Robert W. Baird
    4/21/2022$30.00Outperform
    Oppenheimer
    4/6/2022$21.00Peer Perform
    Wolfe Research
    12/21/2021$47.00Overweight
    Cantor Fitzgerald
    7/28/2021$43.00Overweight
    Cantor Fitzgerald
    7/28/2021$40.00Overweight
    Piper Sandler
    7/27/2021$43.00Buy
    Stifel
    More analyst ratings

    $NYXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Nyxoah S.A.

    H.C. Wainwright initiated coverage of Nyxoah S.A. with a rating of Buy

    7/31/23 8:05:01 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Robert W. Baird initiated coverage on Nyxoah S.A.

    Robert W. Baird initiated coverage of Nyxoah S.A. with a rating of Neutral

    7/19/23 7:19:37 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on Nyxoah S.A. with a new price target

    Oppenheimer initiated coverage of Nyxoah S.A. with a rating of Outperform and set a new price target of $30.00

    4/21/22 7:16:59 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026

    INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U.S. Commercialization Mont-Saint-Guibert, Belgium – January 12, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited fourth quarter and full year 2025 financial and operating results. Preliminary, Unaudited Fourth Quarter and Full Year 2025 R

    1/12/26 4:05:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Publication relating to transparency notification

    REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026, 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BNP Paribas Asset Management On January 8, 2026, Nyxoah received a transparency notification from BNP Paribas Asset Management SA. Based on the notification, BNP Paribas Asset Management Europe SAS holds 1,409,791 voting rights, representing 3.28% of the total number of voting rights on December 31, 2025 (43,026,460). The notificat

    1/12/26 1:00:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference

    Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference Mont-Saint-Guibert, Belgium – December 29, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, Jan. 15, 2026. The Company's presentation will begin at 12:00 pm PT. A live audio webcast of the presentation will be available online on the investor relations page of the Company's website at investors.n

    12/29/25 4:05:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    SEC Filings

    View All

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    1/14/26 4:05:22 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Nyxoah SA

    SCHEDULE 13G - Nyxoah SA (0001857190) (Subject)

    12/29/25 10:03:49 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Nyxoah SA

    6-K - Nyxoah SA (0001857190) (Filer)

    12/19/25 4:11:15 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Leadership Updates

    Live Leadership Updates

    View All

    Nyxoah Appoints John Landry as Chief Financial Officer

    Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry

    11/4/24 4:45:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Appoints Scott Holstine as Chief Commercial Officer

    Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by

    7/15/24 2:00:00 AM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Strengthens its Executive Leadership Team

    Nyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah's Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device

    11/28/23 4:30:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Financials

    Live finance-specific insights

    View All

    Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026

    INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U.S. Commercialization Mont-Saint-Guibert, Belgium – January 12, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported certain preliminary unaudited fourth quarter and full year 2025 financial and operating results. Preliminary, Unaudited Fourth Quarter and Full Year 2025 R

    1/12/26 4:05:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah Reports Third Quarter 2025 Financial and Operating Results

    REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the third quarter of 2025. Recent Financial and Operating Highlights Completed the first commercial implants of U.S. patients, and genera

    11/13/25 4:12:11 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025

    Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025 Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Thursday, November 13, 2025. Company management will host a conference call to discuss financial results that day beginning 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through t

    10/30/25 5:10:00 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    $NYXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nyxoah SA

    SC 13D/A - Nyxoah SA (0001857190) (Subject)

    10/10/24 4:00:17 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Nyxoah SA (Amendment)

    SC 13D/A - Nyxoah SA (0001857190) (Subject)

    5/30/24 5:20:40 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

    SC 13G/A - Nyxoah SA (0001857190) (Subject)

    2/14/24 4:17:59 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care